Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
2.6950
+0.0350 (1.32%)
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of liver diseases, primarily non-alcoholic steatohepatitis (NASH) and related conditions
The company’s lead product candidate aims to address the unmet medical needs of patients suffering from these chronic diseases by targeting the underlying mechanisms of liver damage and fibrosis. Through innovative research and development, Galmed is committed to advancing its pipeline of therapeutic solutions to improve patient outcomes and contribute to the evolving landscape of liver disease management.
![](https://cdn.benzinga.com/files/images/story/2024/11/04/1_0.png?width=1200&height=800&fit=crop)
A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.
Via Benzinga · November 4, 2024
![](https://cdn.benzinga.com/files/images/story/2024/10/02/Nvidia-Logo-On-Mobile-Phone-Screen-Compa.jpeg?width=1200&height=800&fit=crop)
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.
Via Benzinga · October 2, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/20/Stock-Whisper-Index-Logo-6-copy.jpeg?width=1200&height=800&fit=crop)
The Benzinga Stock Whisper Index looks at five stocks seeing increased attention from readers and what could be ahead.
Via Benzinga · September 20, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/19/stock-chart-1863880-1920-60.jpeg?width=1200&height=800&fit=crop)
Galmed Pharmaceuticals Ltd (NASDAQGLMD) shares are surging Thursday after the company announced plans to broaden its drug development activities over the next two years.
Via Benzinga · September 19, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/18/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/Gold-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/opec-oil-shutter.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/Wall-Street-US-stocks.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/22/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 22, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/21/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 21, 2024
![](https://cdn.benzinga.com/files/images/story/2024/07/09/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · July 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
Galmed Pharmaceuticals just reported results for the first quarter of 2024.
Via InvestorPlace · June 22, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/10/Image19.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 10, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/10/pricesmart_-_logo.jpg?width=1200&height=800&fit=crop)
Shares of PriceSmart, Inc. (NASDAQPSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.
Via Benzinga · April 10, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-stock-market.jpg)
Pre-market stock movers are worth diving into on Wednesday morning to get ready for all of the hottest news moving shares today!
Via InvestorPlace · April 10, 2024
![](https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-single.jpg)
Explore three penny stocks primed for significant growth, backed by Strong Buy ratings from Wall Street. Play it high-risk.
Via InvestorPlace · April 10, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/08/image34.jpeg?width=1200&height=800&fit=crop)
Shares of Esperion Therapeutics, Inc. (NASDAQESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations.
Via Benzinga · April 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/08/image44_0.jpg?width=1200&height=800&fit=crop)
Shares of Agenus Inc. (NASDAQAGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. NASDAQ: AGENNASDAQAGEN)
Via Benzinga · April 8, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
GLMD stock results show that Galmed Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 5, 2024
![](https://g.foolcdn.com/editorial/images/769446/scientists-smiling-and-shaking-hands.jpg)
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via The Motley Fool · March 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/11/21/gold-image.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded lower toward the end of trading on Tuesday following the release of FOMC minutes. The Dow traded down 0.17% to 35,092.02 while the NASDAQ fell 0.59% to 14,200.33. The S&P 500 also fell, dropping, 0.17% to 4,539.87.
Via Benzinga · November 21, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/21/american_eagle_-_logo.jpg?width=1200&height=800&fit=crop)
Shares of American Eagle Outfitters, Inc. (NYSEAEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the consensus of $1.28 billion. EPS of $0.49 surpassed the consensus of $0.48.
Via Benzinga · November 21, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/21/image41.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday. The Dow traded down 0.25% to 35,062.35 while the NASDAQ fell 0.81% to 14,168.79. The S&P 500 also fell, dropping, 0.34% to 4,531.77.
Via Benzinga · November 21, 2023